Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Esophageal Neoplasms
  • Esophagogastric Junction
  • Stomach Neoplasms

abstract

  • Bevacizumab can be safely given with chemotherapy even with primary gastric and GEJ tumors in place. The response rate, time to disease progression (TTP), and overall survival are encouraging, with TTP improved over historical controls by 75%. Further development of bevacizumab in gastric and GEJ cancers is warranted.

publication date

  • November 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.08.0887

PubMed ID

  • 17114652

Additional Document Info

start page

  • 5201

end page

  • 6

volume

  • 24

number

  • 33